Liminatus Pharma Warrants
LIMNW
25 hedge funds and large institutions have $837K invested in Liminatus Pharma Warrants in 2025 Q2 according to their latest regulatory filings, with 25 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
44.33% more ownership
Funds ownership: 0% → 44.33% (+44%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CF
Cantor Fitzgerald
New York
|
+$172K |
| 2 |
CS
Clear Street
New York
|
+$158K |
| 3 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$61.6K |
| 4 |
LA
Linden Advisors
New York
|
+$52.7K |
| 5 |
SCM
Saba Capital Management
New York
|
+$45.9K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| $72 | +$59 | +300 | New |
|
LIMNW Hedge Fund Activity: Q2 2025 in Review
25 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Liminatus Pharma Warrants (LIMNW) for Q2 2025, worth a combined $837K.
Buyers outnumbered sellers: 25 funds opened new LIMNW positions and 0 closed out — a net gain of 25 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Cantor Fitzgerald, opening a new position worth an estimated $172K.
- 25 institutional investors held Liminatus Pharma Warrants (LIMNW) as of Q2 2025, up from 0 in Q1 2025.
- Funds reported $837K of Liminatus Pharma Warrants stock for Q2 2025.
- 25 funds opened new Liminatus Pharma Warrants positions in Q2 2025 and 0 closed out, a net change of +25 holders.
- The largest Liminatus Pharma Warrants buyer in Q2 2025 was Cantor Fitzgerald, an estimated $172K added.
Based on aggregated 13F filings for Q2 2025.